Several studies analyzing CALR mutations in MPN have been published since then, reporting triple-negative (negative to JAK2, MPL, and CALR mutations) ET prevalence of 10%–23%.9–11. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.